NO20020813L - UDP-N-acetylglukosamin: Galaktose-<beta>1, 3-N- acetylgalaktosamin-<alfa>-R/ (GlcNAc til GalNAc) <beta>1,6-N-acetylglukosaminyltransferase, C2GnT3 - Google Patents

UDP-N-acetylglukosamin: Galaktose-<beta>1, 3-N- acetylgalaktosamin-<alfa>-R/ (GlcNAc til GalNAc) <beta>1,6-N-acetylglukosaminyltransferase, C2GnT3

Info

Publication number
NO20020813L
NO20020813L NO20020813A NO20020813A NO20020813L NO 20020813 L NO20020813 L NO 20020813L NO 20020813 A NO20020813 A NO 20020813A NO 20020813 A NO20020813 A NO 20020813A NO 20020813 L NO20020813 L NO 20020813L
Authority
NO
Norway
Prior art keywords
c2gnt3
disclosed
dna
methods
beta
Prior art date
Application number
NO20020813A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020813D0 (no
Inventor
Tilo Schwientek
Henrik Clausen
Original Assignee
Glycozym Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycozym Aps filed Critical Glycozym Aps
Publication of NO20020813D0 publication Critical patent/NO20020813D0/no
Publication of NO20020813L publication Critical patent/NO20020813L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20020813A 1999-08-24 2002-02-19 UDP-N-acetylglukosamin: Galaktose-<beta>1, 3-N- acetylgalaktosamin-<alfa>-R/ (GlcNAc til GalNAc) <beta>1,6-N-acetylglukosaminyltransferase, C2GnT3 NO20020813L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15048899P 1999-08-24 1999-08-24
PCT/DK2000/000469 WO2001014535A2 (fr) 1999-08-24 2000-08-24 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc - GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3

Publications (2)

Publication Number Publication Date
NO20020813D0 NO20020813D0 (no) 2002-02-19
NO20020813L true NO20020813L (no) 2002-04-19

Family

ID=22534762

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020813A NO20020813L (no) 1999-08-24 2002-02-19 UDP-N-acetylglukosamin: Galaktose-<beta>1, 3-N- acetylgalaktosamin-<alfa>-R/ (GlcNAc til GalNAc) <beta>1,6-N-acetylglukosaminyltransferase, C2GnT3

Country Status (11)

Country Link
US (5) US6635461B1 (fr)
EP (1) EP1206529B1 (fr)
JP (1) JP4642301B2 (fr)
AT (1) ATE346914T1 (fr)
AU (1) AU775990B2 (fr)
CA (1) CA2384978C (fr)
DE (1) DE60032150T2 (fr)
MX (1) MXPA02001977A (fr)
NO (1) NO20020813L (fr)
NZ (1) NZ517219A (fr)
WO (1) WO2001014535A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335436A1 (fr) * 2000-02-29 2001-08-29 Glycodesign Inc. Nouveaux genes noyaux 2 beta-1,6-n-acetylgylcosaminyltransferase
JP4300267B2 (ja) * 2001-12-28 2009-07-22 独立行政法人産業技術総合研究所 新規ｎ−アセチルグルコサミン転移酵素及びそれをコードする核酸
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20060216273A1 (en) * 2005-03-25 2006-09-28 Min-Chuan Huang Gene therapy for colorectal cancer
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
US20100221763A1 (en) * 2005-10-17 2010-09-02 Health Research, Inc Specific Acceptors for Transferases to Saccharides and Method for Obtaining and Using Same
US9816996B2 (en) * 2011-07-26 2017-11-14 National Institute Of Advanced Industrial Science And Technology Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer
CN108802385B (zh) 2012-02-09 2022-02-08 米密德诊断学有限公司 用于诊断感染的标记和决定因素和其使用方法
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
CN107209184B (zh) 2014-12-11 2020-04-24 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3423590A4 (fr) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. Déterminants d'arn pour différencier des infections bactériennes d'infections virales
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
WO2018011796A1 (fr) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Diagnostic précoce d'infections
CA3027341A1 (fr) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Signatures de proteines permettant d'etablir la difference entre des infections bacteriennes et des infections virales
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (fr) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Procédés d'évaluation de risque et de classification de maladie
CN108192978B (zh) * 2018-03-29 2020-10-27 青岛泱深生物医药有限公司 一种肿瘤相关生物标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60234574A (ja) * 1984-05-08 1985-11-21 日本たばこ産業株式会社 シガレツト製造機における中味たばこ量制御装置
WO1990007000A2 (fr) 1988-12-13 1990-06-28 La Jolla Cancer Research Foundation Nucleotides codant la b1,4-galactosyltransferase humaine et leurs utilisations
US5360733A (en) * 1992-10-01 1994-11-01 La Jolla Cancer Research Foundation Human β1-6 n-acetylglucosaminyl transferase
WO1995007020A1 (fr) * 1993-09-09 1995-03-16 La Jolla Cancer Research Foundation EXPRESSION DE L'ANTIGENE I DE DEVELOPPEMENT PAR UN ADNc CODANT UNE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANFERASE
US5484590A (en) * 1993-09-09 1996-01-16 La Jolla Cancer Research Foundation Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family
US6136580A (en) 1999-01-19 2000-10-24 The Burnham Institute β-1-6-N-acetylglucosaminyltransferase that forms core 2, core 4 and I branches
CA2335436A1 (fr) * 2000-02-29 2001-08-29 Glycodesign Inc. Nouveaux genes noyaux 2 beta-1,6-n-acetylgylcosaminyltransferase

Also Published As

Publication number Publication date
MXPA02001977A (es) 2002-09-18
WO2001014535A3 (fr) 2001-06-21
WO2001014535A2 (fr) 2001-03-01
JP2003507061A (ja) 2003-02-25
EP1206529B1 (fr) 2006-11-29
DE60032150T2 (de) 2007-09-27
US7097994B2 (en) 2006-08-29
US7094887B2 (en) 2006-08-22
US6635461B1 (en) 2003-10-21
US20030180778A1 (en) 2003-09-25
AU6686800A (en) 2001-03-19
EP1206529A2 (fr) 2002-05-22
US20040203111A1 (en) 2004-10-14
NZ517219A (en) 2004-06-25
NO20020813D0 (no) 2002-02-19
DE60032150D1 (de) 2007-01-11
US7078206B2 (en) 2006-07-18
US6794169B2 (en) 2004-09-21
JP4642301B2 (ja) 2011-03-02
AU775990B2 (en) 2004-08-19
ATE346914T1 (de) 2006-12-15
US20030054525A1 (en) 2003-03-20
CA2384978A1 (fr) 2001-03-01
US20040203092A1 (en) 2004-10-14
CA2384978C (fr) 2012-10-23

Similar Documents

Publication Publication Date Title
NO20020813L (no) UDP-N-acetylglukosamin: Galaktose-&lt;beta&gt;1, 3-N- acetylgalaktosamin-&lt;alfa&gt;-R/ (GlcNAc til GalNAc) &lt;beta&gt;1,6-N-acetylglukosaminyltransferase, C2GnT3
ATE408006T1 (de) Udp-galaktose: beta-i(n)-acetyl-glukosamin beta1, 3 galaktosyltransferasen, beta3gal-t5
Okajima et al. Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans
Sato et al. Molecular cloning of a human cDNA encoding β-1, 4-galactosyltransferase with 37% identity to mammalian UDP-Gal: GlcNAc β-1, 4-galactosyltransferase
SUZUKI et al. Arginine kinase evolved twice: evidence that echinoderm arginine kinase originated from creatine kinase
Bauer et al. The family 1 β-glucosidases from Pyrococcus furiosus and Agrobacterium faecalis share a common catalytic mechanism
Telkov et al. Proteins of the Rpf (resuscitation promoting factor) family are peptidoglycan hydrolases
EP2100967A1 (fr) Procédé de production de lacto-n-biose i ou de galacto-n-biose
Takeda et al. Structure/function studies of human beta-cell glucokinase. Enzymatic properties of a sequence polymorphism, mutations associated with diabetes, and other site-directed mutants
ATE302853T1 (de) Pflanzliche (gnti)-sequenzen und verwendung derselben zur gewinnung von pflanzen mit verminderter oder fehlender n- acetylglucosaminyltransferase i (gnti)-aktivität
DK0470145T3 (da) Kartoffel-alfa-amylasegen
Horsburgh et al. LytG of Bacillus subtilis is a novel peptidoglycan hydrolase: the major active glucosaminidase
van der Spoel et al. Processing of lysosomal β-galactosidase: the C-terminal precursor fragment is an essential domain of the mature enzyme
Chen et al. A tetrad of ionizable amino acids is important for catalysis in barley β-glucanases
JP2005516594A (ja) 可溶性ＧｌｃＮＡｃホスフォトランスフェラーゼ
Lemp et al. Molecular cloning and heterologous expression of N-glycosidase F from Flavobacterium meningosepticum.
Eneyskaya et al. An α-L-fucosidase from Thermus sp. with unusually broad specificity
Filipowicz et al. Cyclization of RNA 3'-terminal phosphate by cyclase from HeLa cells proceeds via formation of N (3') pp (5') A activated intermediate.
US11739305B2 (en) Sialyltransferase variants having neosialidase activity
JP4333880B2 (ja) コンドロイチン合成酵素および該酵素をコードするｄｎａ
Neeleman et al. Alpha-lactalbumin affects the acceptor specificity of Lymnaea stagnalis albumen gland UDP-GalNAc: GlcNAc beta-R beta 1--> 4-N-acetylgalactosaminyltransferase: synthesis of GalNAc beta 1--> 4Glc.
JP4338038B2 (ja) コンドロイチン合成酵素および該酵素をコードする核酸
ATE346913T1 (de) Udp-n-acetyl glucosamin: galaktose-batel, 3-n- acetyl galaktosamin-alpha-r/ n-acetyl glucosamin- betal, 3-n-acetyl galaktosamin-alpha-r (glcnac to galnac) betal, 6-n-acetyl glucosaminyl transferase, c2/4gnt
JP3886061B2 (ja) 新規なβ−ガラクトシダーゼ
JP2612687B2 (ja) シクロマルトデキストリングルカノトランスフエラーゼ活性を有するポリペプチド

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application